Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
63.25
+1.25 (2.02%)
At close: Aug 13, 2025, 4:00 PM
60.67
-2.58 (-4.08%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Cidara Therapeutics Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Cidara Therapeutics stock ranges from a low of $35 to a high of $75. The average analyst price target of $57 forecasts a -9.88% decrease in the stock price over the next year.
Price Target: $57.00 (-9.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 7 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $59 → $66 | Buy | Maintains | $59 → $66 | +4.35% | Aug 8, 2025 |
| Needham | Needham | Strong Buy Maintains $54 → $74 | Strong Buy | Maintains | $54 → $74 | +17.00% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $53 → $74 | Strong Buy | Maintains | $53 → $74 | +17.00% | Aug 8, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $59 | Buy | Maintains | $59 | -6.72% | Jun 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $41 → $53 | Strong Buy | Maintains | $41 → $53 | -16.21% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
4.59M
EPS This Year
-8.11
from -26.75
EPS Next Year
-8.20
from -8.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 23.6M | 23.6M | ||
| Avg | n/a | 4.6M | 5.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 414.7% | ||
| Avg | - | - | 25.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.96 | -5.57 | -4.49 | ||
| Avg | -8.11 | -8.20 | -7.09 | ||
| Low | -10.87 | -9.72 | -9.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.